Latest News

Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.
Sintilimab Combo Shows Modest Efficacy, Safety in HER2– Gastric/GEJ Cancer

February 18th 2024

Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.

Investigators of the AMPLIFY-201 trial hypothesized that ELI-002 2P may induce the expansion of functional tumor-directed KRAS-mutated specific T cells following tumor resection.
Cancer Vaccine Shows Efficacy and Safety Potential in PDAC and CRC

February 13th 2024

Findings from the FRUTIGA study support fruquintinib plus paclitaxel as a promising second-line treatment for those with advanced gastric or gastroesophageal junction adenocarcinoma following prior chemotherapy.
Fruquintinib/Paclitaxel Improves PFS, ORR in Gastric/GEJ Adenocarcinoma

February 7th 2024

Adjuvant chemotherapy does not yield an improvement in ctDNA clearance compared with observation among patients with stage II colon cancer in the phase 2/3 COBRA trial.
ctDNA Does Not Confer Chemo Efficacy in Stage II CRC Following Surgery

January 23rd 2024

Total Gastrectomy Associated with Long-term AEs in CDH1 Variants
Total Gastrectomy Associated with Long-term AEs in CDH1 Variants

January 23rd 2024

More News